Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Acrux ( (AU:ACR) ) is now available.
Acrux Limited reported a significant increase in its profit share income for the September quarter, surpassing the total income of the previous financial year. The company’s revenue growth is driven by products launched in FY25, with notable contributions from Nitroglycerin ointment and Dapsone gels. Additionally, Acrux received a substantial R&D Tax Incentive Rebate from the Australian Tax Office and repaid short-term advances from Radium Capital. The company’s strategic focus on its portfolio of topical generics is expected to continue supporting revenue growth in FY26.
More about Acrux
Acrux is a specialty pharmaceutical company with a focus on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, the company has successfully marketed several products worldwide, particularly emphasizing the United States market.
YTD Price Performance: -57.58%
Average Trading Volume: 435,452
Technical Sentiment Signal: Sell
Current Market Cap: A$5.73M
Find detailed analytics on ACR stock on TipRanks’ Stock Analysis page.